JP2018515107A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515107A5
JP2018515107A5 JP2017559449A JP2017559449A JP2018515107A5 JP 2018515107 A5 JP2018515107 A5 JP 2018515107A5 JP 2017559449 A JP2017559449 A JP 2017559449A JP 2017559449 A JP2017559449 A JP 2017559449A JP 2018515107 A5 JP2018515107 A5 JP 2018515107A5
Authority
JP
Japan
Prior art keywords
cells
host
strains
expression
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017559449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515107A (ja
JP7163028B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/060919 external-priority patent/WO2016180982A1/en
Publication of JP2018515107A publication Critical patent/JP2018515107A/ja
Priority to JP2021034586A priority Critical patent/JP7465833B2/ja
Publication of JP2018515107A5 publication Critical patent/JP2018515107A5/ja
Application granted granted Critical
Publication of JP7163028B2 publication Critical patent/JP7163028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017559449A 2015-05-13 2016-05-13 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド Active JP7163028B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021034586A JP7465833B2 (ja) 2015-05-13 2021-03-04 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562160794P 2015-05-13 2015-05-13
US62/160,794 2015-05-13
PCT/EP2016/060919 WO2016180982A1 (en) 2015-05-13 2016-05-13 T cell recruiting polypeptides based on cd3 reactivity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021034586A Division JP7465833B2 (ja) 2015-05-13 2021-03-04 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド

Publications (3)

Publication Number Publication Date
JP2018515107A JP2018515107A (ja) 2018-06-14
JP2018515107A5 true JP2018515107A5 (https=) 2021-04-30
JP7163028B2 JP7163028B2 (ja) 2022-10-31

Family

ID=55971009

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017559449A Active JP7163028B2 (ja) 2015-05-13 2016-05-13 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
JP2021034586A Active JP7465833B2 (ja) 2015-05-13 2021-03-04 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
JP2023068151A Active JP7763804B2 (ja) 2015-05-13 2023-04-18 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
JP2025151363A Pending JP2025186357A (ja) 2015-05-13 2025-09-11 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021034586A Active JP7465833B2 (ja) 2015-05-13 2021-03-04 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
JP2023068151A Active JP7763804B2 (ja) 2015-05-13 2023-04-18 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
JP2025151363A Pending JP2025186357A (ja) 2015-05-13 2025-09-11 Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド

Country Status (17)

Country Link
US (3) US11046767B2 (https=)
EP (2) EP4345112A3 (https=)
JP (4) JP7163028B2 (https=)
CN (4) CN114920848B (https=)
AU (1) AU2016260909B2 (https=)
CA (2) CA3155409A1 (https=)
DK (1) DK3294319T3 (https=)
ES (1) ES2984656T3 (https=)
FI (1) FI3294319T3 (https=)
HR (1) HRP20240971T1 (https=)
HU (1) HUE067423T2 (https=)
LT (1) LT3294319T (https=)
PL (1) PL3294319T3 (https=)
PT (1) PT3294319T (https=)
RS (1) RS65904B1 (https=)
SI (1) SI3294319T1 (https=)
WO (1) WO2016180982A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3155409A1 (en) 2015-05-13 2016-11-17 Ablynx N.V. T cell recruiting polypeptides based on cd3 reactivity
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
AU2018250641B2 (en) 2017-04-11 2025-03-13 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
HRP20241268T1 (hr) 2017-10-13 2024-12-06 Harpoon Therapeutics, Inc. Trispecifični proteini i postupci primjene
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
BR112020020604A2 (pt) 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
AU2019283639A1 (en) * 2018-06-04 2021-01-07 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
WO2019237081A1 (en) * 2018-06-07 2019-12-12 Cullinan Management, Inc. Multi-specific binding proteins and methods of use thereof
US20210269525A1 (en) * 2018-06-29 2021-09-02 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ANTI-CD3e ANTIBODIES AND USES THEREOF
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
US12097219B2 (en) 2018-09-10 2024-09-24 Legend Biotech Ireland Limited Single-domain antibodies against CLL1 and constructs thereof
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
SG11202103022WA (en) * 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
WO2020076992A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
EP3864045A2 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
CN114106183B (zh) 2019-01-15 2023-06-23 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
NL2024375B1 (en) * 2019-12-04 2021-08-31 Apo T B V Methods and means for attracting immune effector cells to tumor cells.
AU2020403273A1 (en) 2019-12-11 2022-06-30 Cullinan Oncology, Inc. Anti-CD19 antibodies and multi-specific binding proteins
CN115380047A (zh) 2020-01-29 2022-11-22 印希比股份有限公司 Cd28单结构域抗体及其多价和多特异性构建体
CN113527496B (zh) * 2020-04-16 2022-03-04 上海洛启生物医药技术有限公司 抗Trop2纳米抗体及其应用
CN111548390B (zh) * 2020-06-17 2022-09-06 清华大学深圳国际研究生院 一种cd133拮抗多肽及其衍生物与应用
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
US11795224B2 (en) * 2021-03-24 2023-10-24 China Medical University Hospital Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same
US11795227B2 (en) * 2021-03-24 2023-10-24 Shine-On Biomedical Co., Ltd. Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
EP4430076A2 (en) * 2021-11-08 2024-09-18 Life Technologies AS Polymer-interaction molecule conjugates and methods of use
CN118574857A (zh) * 2022-01-27 2024-08-30 岩唐生物科技(杭州)有限责任公司 靶向cd3的多特异性抗体及其应用
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
JP2026506075A (ja) 2023-02-17 2026-02-20 アブリンクス エン．ヴェー． 新生児型ｆｃ受容体に結合するポリペプチド
CN121086073A (zh) * 2024-06-07 2025-12-09 广东菲鹏制药股份有限公司 特异性结合cd3/tcr复合物的纳米抗体或其抗原结合片段及其应用
WO2026021698A1 (en) 2024-07-23 2026-01-29 BioNTech SE Nucleic acid particle
WO2026078159A1 (en) 2024-10-10 2026-04-16 Ablynx Nv Immune cell engagers and methods comprising the same

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DE69334095T2 (de) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0702721B1 (en) 1993-06-09 2001-01-03 Unilever N.V. Process for producing fusion proteins comprising scfv fragments by a transformed mould
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
AU3295299A (en) * 1998-02-19 1999-09-06 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
CN1195779C (zh) * 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002355477B2 (en) 2001-08-03 2008-09-25 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
CA2497172A1 (en) 2002-09-10 2004-03-25 Acres Gaming Incorporated Method and device for collecting and reporting data
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
WO2004041867A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1587838B1 (en) 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006122787A1 (en) 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
ES2852423T3 (es) 2005-05-20 2021-09-13 Ablynx Nv NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
EP2220120A2 (en) 2007-11-27 2010-08-25 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
EP2268668A1 (en) 2008-04-17 2011-01-05 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
ES2551854T3 (es) 2009-04-30 2015-11-24 Ablynx N.V. Procedimiento para la producción de anticuerpos de dominio
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
IN2012DN01331A (https=) * 2009-08-31 2015-06-05 Ibc Pharmaceuticals Inc
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
DK2632946T3 (en) 2010-10-29 2018-03-12 Ablynx Nv PROCEDURE FOR MANUFACTURING VARIABLE IMMUNGLOBULIN SINGLE DOMAINS
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
CA2832389A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
DK2723769T4 (da) 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2820047B1 (en) 2012-03-01 2018-04-25 Amgen Research (Munich) GmbH Long life polypeptide binding molecules
WO2014012085A2 (en) * 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
AU2013302696B9 (en) * 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014030049A2 (en) * 2012-08-21 2014-02-27 Glaxo Group Limited Compositions comprising a single variable domain and camostat mesylate (cm)
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
EP2769989A1 (en) * 2013-02-21 2014-08-27 Universitätsklinikum Freiburg Recombinant bispecific antibody that binds to the CD133 antigen on tumor cells and to the human CD3 T cell receptor
EP2981281B1 (en) * 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN105814082A (zh) 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
KR102093343B1 (ko) 2013-10-23 2020-03-25 삼성전자주식회사 이미지 센서 및 이미지 센서를 구동하는 방법
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
CA3155409A1 (en) 2015-05-13 2016-11-17 Ablynx N.V. T cell recruiting polypeptides based on cd3 reactivity

Similar Documents

Publication Publication Date Title
JP2018515107A5 (https=)
CN112955547B (zh) 通过使用转录因子来增加蛋白质表达的手段和方法
KR20160059994A (ko) 두 개의 벡터로부터 발현된 Cas9 단백질을 이용한 유전자 발현 조절 방법
Athmaram et al. Influence of copy number on the expression levels of pandemic influenza hemagglutinin recombinant protein in methylotrophic yeast Pichia pastoris
KR20180117147A (ko) 진핵생물을 위한 발현 시스템
US20230144097A1 (en) Active dna transposon systems and methods for use thereof
JP2022514603A (ja) 藻類における遺伝子の誘導発現
KR20230157387A (ko) Cas 효소를 이용한 다중 편집
EP0093062B1 (fr) ADN contenant une séquence codant pour une protéine du cristal ou un polypeptide doué de propriétés insecticides, micro-organismes transformés par de tels ADN, compositions contenant lesdites protéines du cristal, polypeptide ou micro-organismes
JPWO2018110471A1 (ja) 転写調節融合ポリペプチド
JP5932766B2 (ja) Ｖｐｓ遺伝子が破壊されている酵母を用いる異種タンパク質の製造方法
JP2024528145A (ja) タンパク質合成および分泌のための方法および組成物
US11214809B2 (en) Vector containing centromere DNA sequence and use thereof
JP2000136199A (ja) シゾサッカロミセス・ポンベで使用可能なシグナルペプチド、分泌型発現ベクター、およびそれらを用いたタンパク質生産方法
JP2011507507A (ja) マルチマー性前駆体のｉｎｖｉｖｏタンパク質分解的プロセシングによる関心対象のタンパク質の分泌収量の改善
CN117448324A (zh) 基于CRISPR/Cas9系统高效编辑水牛H11位点的gRNA
JP6944697B2 (ja) 糸状菌におけるゲノム編集を用いる多段階による多重変異株の製造方法
EP1930423A1 (en) Expression vector, transformant having the expression vector introduced therein, and process for production of heterologous protein
JP4531570B2 (ja) 封入体結合タンパク質をコードする遺伝子（ｉｂｐＡおよび／またはｉｂｐＢ）を欠失あるいは増幅させて目的タンパク質を製造する方法
CA2413612A1 (fr) Vecteurs d'expression comprenant un fragment modifie de l'operon tryptophane
Wanarska et al. A new expression system based on psychrotolerant debaryomyces macquariensis yeast and its application to the production of cold-active β-d-galactosidase from paracoccus sp. 32d
US10266834B2 (en) Recombinant RNA particles and methods of producing proteins
JP6698993B2 (ja) ピキア酵母を用いた遺伝子組換えによるアスパルティックプロテアーゼの製造方法
FR2947840A1 (fr) Sequence promotrice pour l'expression de proteines recombinantes chez lactococcus lactis
JPWO2017170418A1 (ja) エンドヌクレアーゼ活性を有するポリペプチド及びその製造方法